Navigation Links
Arthritis drugs safer than previously declared

A recently done review of findings published earlier, proves that the previous report exaggerated the risk that two drugs// show in raising the risk of cancer in those who use them.

Research done by Dr. Eric Matteson and colleagues at the Mayo Clinic in Rochester, New York in May 2006, dealing with the study of two drugs 'Humira' and 'Remicade' used currently by physicians to treat rheumatoid arthritis surfaced with findings that pointed out a heavy probability of development of cancer and infections like tuberculosis, in those who use them regularly.This information was was exhibited on labels according to the order of the FDA six months earlier.

However several teams of researchers have since then studied the same drugs all over again in a review to re affirm if they actually triple the chances of cancerous lesions and infections. Their review has projected new data which hints that risk of cancer is not as high as that was proclaimed in the previous studies. The Journal of the American Medical Association has published a number of letters from researchers who have reviewed the drugs again which claims that the use of drug Humira and Remicade only doubles the chances of carcinoma and may work against other auto immune diseases such as skin conditions such as psoriasis, ulcerative colitis.

Almost all the researchers, and the U.S. FDA feel in unison that it is the right of every to know about the risks but also opine that the benefits reflect that the drugs should stay on the market.

Matteson and his colleagues re did the analysis done in May and after considering certain data which were not analysed earlier reached the conclusion that the drugs may not triple the chances of cancer but only double the chances as these two drugs act on the auto immune system blocking the action of TNF-alpha one of the target compounds which mistakenly signals to the immune system to attack the joints as in rheumatoid arthritis.It is now an established fact that any drug that is capable of modifying the immune system can also cause cancer.

Another drug of the same class Enbrel is also being studied by researchers to look into possibilities of causing cancer or infections.

The market for drugs to treat Rheumatoid arthritis is on an upswing following the increase in number of Americans that are affected by rheumatoid arthritis according to the findings noted by market research company Research and Markets.
MST
'"/>




Related medicine news :

1. Another ray of hope for Arthritis Sufferers
2. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
3. B Vitamin protects and lowers toxicity of Arthritis Drug
4. FDA Approves New Arthritis Drug, Bextra
5. Risk Of Developing Arthritis
6. Arthritis Drug May Cause Liver Damage
7. Arthritis drug can prolong life
8. New treatment for Rheumatoid Arthritis
9. Important cause of Arthritis
10. Personality Impacts Arthritis
11. New Rheumatoid Arthritis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... ... 2017 , ... Patients interested in receiving quick and effective ... Cameron, with or without a referral. The FASTBRACES system is valued for its ... patient’s case, treatment with the FASTBRACES system could be completed in 120 days ...
(Date:3/29/2017)... ANN ARBOR, Mich. (PRWEB) , ... ... ... Global Retailer and Manufacturer Alliance (GRMA) is growing as it continues developing ... the dietary supplement industry. The organization, which plans to publish the first ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... oral braces. "The rubber bands used in conjunction with my braces always rubbed ... to design a way to prevent this problem." The O.B.S. was the result ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly ... assembly protocols involve many repetitive steps and often scientists require many different versions ... high-throughput needed, and results in a lower error rate and cost saving for ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  Novartis announced today ... has accepted the company,s Biologics License Application (BLA) ... an investigational chimeric antigen receptor T cell (CAR-T) ... young adult patients with B-cell acute lymphoblastic leukemia ... Novartis for a CAR-T. The priority review designation ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "South ... & Forecast" report to their offering. ... The South Korean Proton Therapy Market is expected to ... Untapped Proton Therapy Market for South Korea was ... Proton Therapy plays an important role in delivering comprehensive cancer care to ...
(Date:3/29/2017)... 29, 2017  Zynex (OTCQB: ZYXI), an innovative medical technology ... medical devices for pain management, stroke rehabilitation, cardiac monitoring ... the Company,s 2016 full-year investor webcast on Monday, April 3, ... The Company expects to file its 2016 full year ... ...
Breaking Medicine Technology: